BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1444 related articles for article (PubMed ID: 23287853)

  • 1. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.
    Dong X; Lin D; Low C; Vucic EA; English JC; Yee J; Murray N; Lam WL; Ling V; Lam S; Gout PW; Wang Y
    J Thorac Oncol; 2013 Feb; 8(2):161-70. PubMed ID: 23287853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of survivin expression in stage III non-small cell lung cancer patients treated with platinum-based therapy.
    Cho HJ; Kim HR; Park YS; Kim YH; Kim DK; Park SI
    Surg Oncol; 2015 Dec; 24(4):329-34. PubMed ID: 26690822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SIRT5 facilitates cancer cell growth and drug resistance in non-small cell lung cancer.
    Lu W; Zuo Y; Feng Y; Zhang M
    Tumour Biol; 2014 Nov; 35(11):10699-705. PubMed ID: 25070488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of TAZ expression in resected non-small cell lung cancer.
    Xie M; Zhang L; He CS; Hou JH; Lin SX; Hu ZH; Xu F; Zhao HY
    J Thorac Oncol; 2012 May; 7(5):799-807. PubMed ID: 22481233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced miR-3127-5p expression promotes NSCLC proliferation/invasion and contributes to dasatinib sensitivity via the c-Abl/Ras/ERK pathway.
    Sun Y; Chen C; Zhang P; Xie H; Hou L; Hui Z; Xu Y; Du Q; Zhou X; Su B; Gao W
    Sci Rep; 2014 Oct; 4():6527. PubMed ID: 25284075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphorylated tubulin adaptor protein CRMP-2 as prognostic marker and candidate therapeutic target for NSCLC.
    Oliemuller E; Peláez R; Garasa S; Pajares MJ; Agorreta J; Pío R; Montuenga LM; Teijeira A; Llanos S; Rouzaut A
    Int J Cancer; 2013 May; 132(9):1986-95. PubMed ID: 23023514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serpin b3 is associated with poor survival after chemotherapy and is a potential novel predictive biomarker in advanced non-small-cell lung cancer.
    Urquhart G; Kerr KM; Nicolson M; Loo PS; Sharma R; Shrimali R; Petty RD
    J Thorac Oncol; 2013 Dec; 8(12):1502-9. PubMed ID: 24389432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CXCR4 promotes cisplatin-resistance of non-small cell lung cancer in a CYP1B1-dependent manner.
    Xie S; Tu Z; Xiong J; Kang G; Zhao L; Hu W; Tan H; Tembo KM; Ding Q; Deng X; Huang J; Zhang Q
    Oncol Rep; 2017 Feb; 37(2):921-928. PubMed ID: 27922681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platinum-Vinorelbine Induction Chemotherapy plus Bevacizumab With and Without Pemetrexed Switch Maintenance in Advanced NSCLC.
    Michelsen L; Sørensen JB
    Anticancer Res; 2015 Nov; 35(11):6255-9. PubMed ID: 26504059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups.
    Schmidt LH; Kümmel A; Görlich D; Mohr M; Bröckling S; Mikesch JH; Grünewald I; Marra A; Schultheis AM; Wardelmann E; Müller-Tidow C; Spieker T; Schliemann C; Berdel WE; Wiewrodt R; Hartmann W
    PLoS One; 2015; 10(8):e0136023. PubMed ID: 26313362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytoplasmic Ape1 expression elevated by p53 aberration may predict survival and relapse in resected non-small cell lung cancer.
    Wu HH; Chu YC; Wang L; Tsai LH; Lee MC; Chen CY; Shieh SH; Cheng YW; Lee H
    Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S336-47. PubMed ID: 22688662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 non-small-cell lung cancer.
    Liao WY; Chen JH; Wu M; Shih JY; Chen KY; Ho CC; Yang JC; Yu CJ
    Clin Lung Cancer; 2013 Jul; 14(4):418-24. PubMed ID: 23291258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ly6/uPAR-related protein C4.4A as a marker of solid growth pattern and poor prognosis in lung adenocarcinoma.
    Jacobsen B; Muley T; Meister M; Dienemann H; Christensen IJ; Santoni-Rugiu E; Lærum OD; Ploug M
    J Thorac Oncol; 2013 Feb; 8(2):152-60. PubMed ID: 23287851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological significance of KAI1 expression and epithelial-mesenchymal transition in non-small cell lung cancer.
    Zhou L; Yu L; Wu S; Feng Z; Song W; Gong X
    World J Surg Oncol; 2015 Aug; 13():234. PubMed ID: 26231404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CXCR4 overexpression is associated with poor outcome in females diagnosed with stage IV non-small cell lung cancer.
    Otsuka S; Klimowicz AC; Kopciuk K; Petrillo SK; Konno M; Hao D; Muzik H; Stolte E; Boland W; Morris D; Magliocco AM; Bebb DG
    J Thorac Oncol; 2011 Jul; 6(7):1169-78. PubMed ID: 21623238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High coexpression of both EGFR and IGF1R correlates with poor patient prognosis in resected non-small-cell lung cancer.
    Gately K; Forde L; Cuffe S; Cummins R; Kay EW; Feuerhake F; O'Byrne KJ
    Clin Lung Cancer; 2014 Jan; 15(1):58-66. PubMed ID: 24210543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic stratification of stage IIIA pN2 non-small cell lung cancer by hierarchical clustering analysis of tissue microarray immunostaining data: an Alpe Adria Thoracic Oncology Multidisciplinary Group study (ATOM 014).
    Grossi F; Spizzo R; Bordo D; Cacitti V; Valent F; Rossetto C; Follador A; Di Terlizzi S; Aita M; Morelli A; Fasola G; Consiglieri C; Ceschia T; Beltrami CA; Belvedere O
    J Thorac Oncol; 2010 Sep; 5(9):1354-60. PubMed ID: 20631638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I/II and pharmacokinetic study of intravenous vinflunine in combination with cisplatin for the treatment of chemonaive patients with advanced non-small-cell lung cancer.
    Souquet PJ; Krzakowski M; Ramlau R; Sun XS; Lopez-Vivanco G; Puozzo C; Pouget JC; Pinel MC; Rosell R
    Clin Lung Cancer; 2010 Mar; 11(2):105-13. PubMed ID: 20199976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive value of expression of P53, Bcl-2 and lung resistance-related protein for response to chemotherapy in non-small cell lung cancers.
    Harada T; Ogura S; Yamazaki K; Kinoshita I; Itoh T; Isobe H; Yamashiro K; Dosaka-Akita H; Nishimura M
    Cancer Sci; 2003 Apr; 94(4):394-9. PubMed ID: 12824911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of CD133 expression in the carcinogenesis and prognosis of patients with lung cancer.
    Le H; Zeng F; Xu L; Liu X; Huang Y
    Mol Med Rep; 2013 Nov; 8(5):1511-8. PubMed ID: 24008862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 73.